

Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal)

Technology appraisal guidance

Published: 14 December 2011

[nice.org.uk/guidance/ta240](https://www.nice.org.uk/guidance/ta240)

Contents

Advice	3
Background.....	4
Information.....	5

This guidance is partially replaced by TA439.

Advice

NICE is unable to recommend panitumumab with 5 fluorouracil, folinic acid and irinotecan (FOLFIRI) for previously treated metastatic colorectal cancer in adults because no evidence submission was received from the manufacturer or sponsor of the technology.

Since the publication of TA240, the population covered by the marketing authorisation for panitumumab has changed from 'patients with wild-type KRAS metastatic colorectal cancer' to 'patients with wild-type RAS metastatic colorectal cancer'.

Background

The manufacturer of panitumumab (Amgen) was invited to submit evidence for this single technology appraisal of panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer.

In July 2011, Amgen informed NICE that it would not be making an evidence submission. Amgen stated that, taking into account approaches previously used by NICE to appraising drugs for the treatment of colorectal cancer, there was not sufficient evidence to robustly estimate the cost effectiveness of panitumumab for this indication.

NICE has therefore terminated this single technology appraisal.

Information

NHS organisations should take into account the reasons why the company did not make an evidence submission when considering whether or not to recommend local use of panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer. If, after doing this, organisations still wish to consider panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer, they should follow the advice on rational local decision-making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when NICE guidance is unavailable.

NICE will review the position if the company decides that it wants to make a full submission.

ISBN: 978-1-4731-2442-4

Accreditation

